The aim of this phase III study is to assess the efficacy of abnobaVISCUM? 900 compared with Mitomycin C (MMC) monotherapy in patients with superficial bladder carcinoma by evaluation of the time to tumor recurrence. Secondary objective is to evaluate the safety of abnobaVISCUM? 900, in particular, to compare the toxicity of the two treatments. Another secondary objective is the treatment efficacy as measured by calculated prognosis for recurrence and progression after 1 year, the tumor grading in case of a recurrence and by measurement of Quality of Life.

Start Date01 Apr 2015

Sponsor / Collaborator

Abnoba GmbH

NCT02191540

/ CompletedPhase 3

A Phase 3, Multi-Center, Single-Arm, Open-Label Study For The Safety And Efficacy Of Mistletoe Extract (AbnobaViscum® Injection) In Malignant Pleural Effusions

Phase 3, non-randomized, Multicenter, single arm study to assess efficacy and safety of Abnoba viscum F 20mg in patients with malignant pleural effusion

Start Date01 Jan 2011

Sponsor / Collaborator

Abnoba Korea, Inc.

[+1]

NCT01401075

/ CompletedPhase 4

Prospective Controlled Randomized Comparative Study About Quality of Life (QoL), Immunomodulation and Safety of Adjuvant Mistletoe Treatment in Patients With Gastric Carcinoma Receiving Chemotherapy After Operation

Evaluation of safety and efficacy of a standardized mistletoe extract (abnobaVISCUM® Quercus, aVQ) in patients with gastric cancer receiving oral chemotherapy.

Start Date01 Mar 2006

Sponsor / Collaborator

Abnoba GmbH

100 Clinical Results associated with Abnoba GmbH

0 Patents (Medical) associated with Abnoba GmbH

Literatures (Medical) associated with Abnoba GmbH

01 Dec 2025·International Journal of Pharmaceutics-X

Galactosylated liposomes for targeted encapsulation and enhanced cytotoxicity of Mistletoe Lectin, an antitumoral type 2 ribosome-inactivating protein

Article

Author: Leneweit, Gero ; Cetin, Eray ; Rieger, Harden ; Kraus, Tiana ; Kaufmann, Josanna

The development of efficient liposomal encapsulations of proteins for pharmaceutical applications is limited by several factors: their high molecular weight, interactions with surrounding substances, or the generally lower stability compared to small molecules. In this work, various liposomal formulations were prepared using the thin-film hydration method followed by extrusion, to investigate their suitability for the encapsulation of the plant-derived antitumoral mistletoe lectin-1 (ML-1). This can be significantly optimized by exploiting its preferential binding to galactose-containing structures, such as modified lipids integrated into the liposomal bilayer. Incorporation of the galactosylated lipid DSPE-PEG2k-Gal into the membrane significantly enhanced the overall recovery rate and encapsulation efficiency of ML-1, attributed to its affinity for the functionalized component. Compared to non-functionalized liposomes, a 2-fold to 4-fold increase in percentage encapsulation efficiency was observed. The galactosylated lipid optimized the ratio of encapsulated to surface-adsorbed ML-1 and facilitated its preferential localization within the core of the liposomes. A strong correlation was identified between the number of entrapped ML-1 molecules per liposome and the degree of galactosylation. The formulations demonstrated high in vitro cytotoxicity, as exemplified with murine colon-26 carcinoma cells, with the galactose-functionalized liposomes achieving an IC₅₀ value comparable to free ML-1. This strategy presents significant potential for developing more efficient and targeted liposomal formulations of pharmaceutical proteins with specific affinities to tailored lipid components, advancing drug delivery technologies, and improving therapeutic options for cancer treatment.

01 Nov 2018·European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.VQ2 · MEDICINE

Thermosensitive liposomes for triggered release of cytotoxic proteins

Q2 · MEDICINE

Article

Author: Leneweit, Gero ; Mastrobattista, Enrico ; de Matos, Maria B C ; Beztsinna, Nataliia ; Schiffelers, Raymond M ; Fens, Marcel H A M ; Heyder, Christoph ; Kok, Robbert J

Lysolipid-containing thermosensitive liposomes (LTSL) are clinically-relevant drug nanocarriers which have been used to deliver small molecule cytostatics to tumors in combination with local hyperthermia (42 °C) to trigger local drug release. The objective of this study was to investigate the feasibility of LTSL for encapsulation and triggered release of macromolecular drugs such as plant-derived cytotoxins. As therapeutic protein we used Mistletoe lectin-1 (ML1) - a ribosome-inactivating protein with potent cytotoxic activity in tumor cells. Model macromolecules (dextrans, albumin) and ML1 were encapsulated in small unilamellar LTSL with varying lipid compositions by the thin film hydration method and extrusion. LTSLs showed molecular weight dependent heat-triggered release of the loaded cargo. The most promising composition, ML1 formulated in LTSL composed of 86:10:4 %mol DPPC:MSPC:DSPE-PEG₂₀₀₀, was further studied for bioactivity against murine CT26 colon carcinoma cells. Confocal live-cell imaging showed uptake of released ML1 after mild hyperthermia at 42 °C, subsequently leading to potent cytotoxicity by LTSL-ML1. Our study shows that LTSL in combination with localized hyperthermia hold promise as local tumor delivery strategy for macromolecular cytotoxins.

01 Jan 2018·International journal of medicinal mushroomsQ4 · BIOLOGY

Effects of Birch Polypore Mushroom, Piptoporus betulinus (Agaricomycetes), the "Iceman’s Fungus", on Human Immune Cells

Q4 · BIOLOGY

Article

Author: Meier, Stefanie ; Steinborn, Carmen ; Alresly, Zeyad ; Wille, Radim ; Grunewald, Franziska ; Huber, Roman ; Lindequist, Ulrike ; Gründemann, Carsten

Piptoporus betulinus, the mushroom that has been carried by Ötzi the "Iceman", has a long tradition of use in medicinal practice for its antiseptic, anticancer, and immune-enhancing properties. With this study, we aimed to investigate the immunomodulatory effects of P. betulinus on primary human immunocompetent cells. The influence of P. betulinus water and methanol extract on apoptosis and necrosis induction of T cells and monocytes was analyzed using annexin V/propidium iodide staining and proliferation of T cells by carboxyfluorescein diacetate succinimidyl ester staining using flow cytometry. The effects on T-cell activation (CD69/CD25) and dendritic cell maturation (CD83, CD86, and CD14) were assessed using flow cytometric analysis of distinct marker expression. Alterations of the secretion of effector mediators interferon (IFN)-γ by T cells and interleukin (IL)-8 by monocytes and dendritic cells were detected by enzyme-linked immunosorbent assay. None of the P. betulinus extracts had a significant influence on apoptosis and necrosis induction, T-cell proliferation, or T-cell activation status, but P. betulinus water extract caused a strong increase in IFN-γ release. The same extract was slightly protective against apoptosis of monocytes and further triggered IL-8 secretion by monocytes and dendritic cells. Moreover, P. betulinus water extract induced dendritic cell maturation. Our results demonstrate the immune-enhancing properties of P. betulinus.

News (Medical) associated with Abnoba GmbH

21 Jan 2020

·www.gliocure.com

RELIEF, a strategic project for GlioCure, selected by EUREKA!

Angers, France - GlioCure SAS, a biotechnology company specialized in neuro-oncology, announces that the RELIEF project, in which it is a partner alongside the German SME Abnoba and the Universities of Angers (France), Utrecht (Netherlands) and Uppsala (Sweden), has been selected by the intergovernmental association for the promotion of innovation EUREKA! through its twelfth Eurostars call for projects. The RELIEF project aims to develop a drug delivery system (functionalized asymmetric liposomes) to better target and treat brain tumours after intravenous injections. The first indication targeted is glioblastoma (GBM) - the most frequent and aggressive brain tumour - with the GC01 peptide developed by GlioCure as the active pharmaceutical ingredient. RELIEF represents a 3-year global R&D effort of approximately €2.8M for the five partners, including €630,000 for GlioCure which will provide the GC01 peptide and assume responsibility for tasks related to in vitro and in vivo anti-GBM activity proof-of-concept . As such, GlioCure could receive up to €252,000 in grants from Bpifrance over the next three years, representing 40% of its R&D effort on the project. "The RELIEF project is strategic for GlioCure as it broadens our pharmaceutical and galenic development options for our first anti-tumor molecule" according to Louis-Marie Bachelot, President and co-founder of GlioCure. He also underlines that "the selection of this project under the Eurostars scheme is a new demonstration, after the selection of the Gliogel project by EuroNanomed III in 2017, of GlioCure's ability to be part of collaborative R&D excellence projects at the European level". The RELIEF project has been labellised by the Atlanpole Biothérapies competitiveness cluster of which GlioCure and the University of Angers are members. About GlioCure : GlioCure is a spin-off of the Universities of Angers and McGill Montreal specialized in neuro-oncology. Positioned in the field of diseases affecting glial cells, cells that are essential to the proper functioning of neurons and the brain, GlioCure is dedicated to identifying, selecting and developing new molecules of interest, particularly for the treatment of brain tumors. GlioCure has thus initiated the development of a first active ingredient, GC01, in the treatment of glioblastoma, the most frequent and aggressive brain tumor. More information is available on our website: www.gliocure.com. Media and Investor Relations Contacts : Louis-Marie Bachelot, Chairman, +33(0)6 14 03 38 26, lm.bachelot@gliocure.com

100 Deals associated with Abnoba GmbH

100 Translational Medicine associated with Abnoba GmbH

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 02 Apr 2026

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 3

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Viscum album extract	Non-Muscle Invasive Bladder Neoplasms More	Phase 3

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis